Collaborative

Xlife Sciences AG

News

Press Releases

20.6.22
Shareholders approve all agenda items for the Annual General Meeting 2022
16.5.22
Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project
29.3.22
xprot, a project company of Xlife Sciences, signes cooperation agreement with the University of Mainz and the Thoraxklinik Heidelberg
Archive

Ad hoc News

9.5.2022
Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario
29.4.2022
Annual Report 2021 (only available in german)
25.4.2022
License partner of Xlife Sciences announces successful completion of phase 1 of in-vivo trial for ATROSIMAB – out-licensing of the compound intended
21.4.2022
Xlife Sciences: Date of publication Annual Report 2022
8.3.2022
Laxxon Medical, a project company of Xlife Sciences, wins Evonik as investor and partner
11.2.2022
Xlife Sciences' shares begin trading on SIX Swiss Exchange
8.2.2022
Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange
1.2.2022
Listing and first trading day on the “Sparks” segment of SIX Swiss Exchange expected for February 11, 2022
10.1.2022
Xlife Sciences (XLS DE) plans listing on the “Sparks” segment of SIX Swiss Exchange
18.11.2021
Xlife Sciences (XLS DE) explores listing on SIX Swiss Exchange
26.10.2021
Partnership with Vision 2030
10.6.2021
Xlife Sciences AG (XLS DE): Breakthrough in Drug Development
31.3.2021
Xlife Sciences AG (XLS): 2020 financial results
17.2.2021
Xlife Sciences AG (XLS): Antiviral drug candidate
8.1.2021
Xlife Sciences AG: Transaction with Baliopharm AG
23.12.2020
Xlife Sciences AG: Exit of a project company
5.8.2020
Xlife Sciences AG: Xlife Sciences takes stake in palleos healthcare
11.3.2020
Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)
14.2.2020
Xlife Sciences AG: Announcement of «Private Placement» capital increase (German only)
22.11.2019
Xlife Sciences AG: Xlife Sciences AG issues convertible bond (German only)

Current share price data & key figures can be found HERE

Current management-transactions can be found HERE

Current listing of major investors can be found HERE

HERE you can find the Articles of Association of Xlife Sciences AG 

Management transactions

21.1.2022
Director's Dealings Xlife Sciences AG
19.1.2022
Director's Dealings Xlife Sciences AG
14.1.2022
Director's Dealings Xlife Sciences AG
20.12.2021
Director's Dealings Xlife Sciences AG
16.12.2021
Director's Dealings Xlife Sciences AG
15.12.2021
Director's Dealings Xlife Sciences AG
10.12.2021
Director's Dealings Xlife Sciences AG
7.12.2021
Director's Dealings Xlife Sciences AG
3.12.2021
Director's Dealings Xlife Sciences AG
29.11.2021
Director's Dealings Xlife Sciences AG
29.11.2021
Director's Dealings Xlife Sciences AG
24.11.2021
Director's Dealings Xlife Sciences AG
24.11.2021
Director's Dealings Xlife Sciences AG
24.11.2021
Director's Dealings Xlife Sciences AG
3.11.2021
Director's Dealings Xlife Sciences AG
3.11.2021
Director's Dealings Xlife Sciences AG
14.10.2021
Director's Dealings Xlife Sciences AG
13.10.2021
Director's Dealings Xlife Sciences AG
13.10.2021
Director's Dealings Xlife Sciences AG
13.10.2021
Director's Dealings Xlife Sciences AG
13.10.2021
Director's Dealings Xlife Sciences AG
13.10.2021
Director's Dealings Xlife Sciences AG
19.7.2021
Director's Dealings Xlife Sciences AG
19.7.2021
Director's Dealings Xlife Sciences AG
19.7.2021
Director's Dealings Xlife Sciences AG
9.7.2021
Director's Dealings Xlife Sciences AG
7.7.2021
Director's Dealings Xlife Sciences AG
2.7.2021
Director's Dealings Xlife Sciences AG
2.7.2021
Director's Dealings Xlife Sciences AG
2.7.2021
Director's Dealings Xlife Sciences AG
2.7.2021
Director's Dealings Xlife Sciences AG
2.7.2021
Director's Dealings Xlife Sciences AG
2.7.2021
Director's Dealings Xlife Sciences AG
28.6.2021
Director's Dealings Xlife Sciences AG
25.6.2021
Director's Dealings Xlife Sciences AG
11.6.2021
Director's Dealings Xlife Sciences AG
3.6.2021
Director's Dealings Xlife Sciences AG
20.5.2021
Director's Dealings Xlife Sciences AG
20.5.2021
Director's Dealings Xlife Sciences AG
7.5.2021
Director's Dealings Xlife Sciences AG
7.4.2021
Director's Dealings Xlife Sciences AG
7.4.2021
Director's Dealings Xlife Sciences AG
16.3.2021
Director's Dealings Xlife Sciences AG
5.3.2021
Director's Dealings Xlife Sciences AG
5.3.2021
Director's Dealings Xlife Sciences AG
5.3.2021
Director's Dealings Xlife Sciences AG
17.2.2021
Director's Dealings Xlife Sciences AG
17.2.2021
Director's Dealings Xlife Sciences AG
21.1.2021
Director's Dealings Xlife Sciences AG
5.11.2020
Director's Dealings Xlife Sciences AG
4.11.2020
Director's Dealings Xlife Sciences AG
11.6.2020
Director's Dealings Xlife Sciences AG
17.1.2020
Director's Dealings Xlife Sciences AG

Financial Reports

May 9, 2022
Xlife Sciences AG Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement

Please contact us

We are here for you.
ir@xlifesciences.ch
+41 44 385 84 60

Sign up for our media releases

We regularly report on the business development of Xlife Sciences AG and our project companies.